TABLE 1 | Irritable bowel syndrome drugs on the market and in clinical development
From the following article:
Ted T. Ashburn & Meera S. Gupta
Nature Reviews Drug Discovery 5, 99-100 (February 2006)
doi:10.1038/nrd1961
| Compound (Brand) | Company | Indication | Phase | Comments |
|---|---|---|---|---|
| Alosetron (Lotronex) | GlaxoSmithKline | IBS-d | Market | 5-HT3 antagonist; 'black box' warning; for women only |
| Tegaserod (Zelnorm) | Novartis | IBS-c | Market | 5-HT4 partial agonist; for women only |
| Cilansetron (Calmactin) | Solvay | IBS-d | III | 5-HT3 antagonist; development discontinued in the U.S. |
| Ramosetron (Nasea) | Astellas | IBS-d | III | 5-HT3 antagonist; in Phase III in Japan and Phase II in Europe |
| Dexloxiglumide | Rotta | IBS-c | III/IIb | Cholecystikinin (CCK)1 antagonist; in development in Europe |
| Lubiprostone | Sucampo | IBS-c | III/IIb | Cl- channel activator; Takeda has North American rights |
| Renzapride | Alizyme | IBS-c | III/IIb | 5-HT3 antagonist + 5-HT4 agonist |
| Saredutant | Sanofi-Aventis | IBS-d/IBS-c | IIb | Neurokinin (NK)2 antagonist |
| Dextofisopam | Vela | IBS-d/IBS-c | II | Benzodiazepine-like molecule |
| E-3620 | Eisai | IBS-c | II | 5-HT3 antagonist + 5-HT4 agonist |
| GTP-010 | Gastrotech | IBS-d/IBS-c | II | GLP-1 analogue; Phase II in the Europe; partnered with Eli Lilly |
| Mitemcinal | Chugai | IBS-c | II | Motilin agonist; also in development for gastroparesis |
| PD-217,014 | Pfizer | IBS-d/IBS-c | II |  2 N-type Ca2+ channel modulator |
| AZD-7371 | AstraZeneca | IBS-d | II | Serotonin modulator |
| Crofelemer | Trine | IBS-d | II | Cl- secretion blocker; natural product |
| Talnetant | GSK | IBS-d/IBS-c | II | Neurokinin (NK)3 antagonist |
| DDP733/pumosetrag | Dynogen | IBS-c | IIa | A minimally absorbed, locally acting 5-HT3 partial agonist |
| DDP225 | Dynogen | IBS-d | IIa | Noradrenaline reuptake inhibitor and 5-HT3 antagonist |
| Asimadoline | Tioga | IBS-d/IBS-c | IIa |  -opioid agonist; Tioga (spin-out of Merck KGaA) |
| Nepadutant | Menarini | IBS-d/IBS-c | IIa | Neurokinin (NK)2 antagonist |
| VISCOL | Salix | IBS-c | IIa | Sodium phosphate, marketed in US as bowel purgative |
Download file
If the slide opens in your browser, select "File > Save As" to save it.
